课题组长期致力于肿瘤、炎症性皮肤病、皮肤感染等疾病的药物治疗研究，依托上海中药外用制剂创新工程技术研究中心，配备独立细胞房以及UPLC-MS、HPLC、电位粒径仪、荧光显微镜、高压均质机等各类科研仪器设备。

课题组目前在研国家自然科学基金8项，省部级课题7项，累计科研经费2000余万元。现有专职科研人员5名、博士后4名、博士生6名、硕士生15名。近五年课题组发表SCI论文100余篇，其中影响因子10分以上的13篇，授权发明专利15项、PCT专利1项。

(1) 国家自然科学基金面上项目， 82373274，融合记忆样NK细胞-焦亡肿瘤的仿生囊泡型疫苗新策略及抗黑色素瘤转移的机制研究，49万，2024/01-2027/12，在研，主持

(2) 国家自然科学基金面上项目，82073385，富氧M1型巨噬细胞携载光敏药物用于肿瘤供氧干预和光动力协同治疗的机制研究，55万，2021/01-2024/12，在研，主持

(3) 上海市“科技创新行动计划”上海工程技术研究中心与专业技术服务平台项目，20DZ2255200，上海中药外用制剂创新工程技术研究中心，500万，2020/12-2022/11，已结题，主持

(4) 上海市“科技创新行动计划”生物医药科技支撑项目，23S11901300，基于PROTAC技术的高选择性JAK1降解剂外用治疗特应性皮炎的临床前研究，40万，2023/04-2026/03，在研，主持

(5) 上海市“科技创新行动计划” 实验动物研究领域项目, 21140901900，基于 3D 生物打印技术的人体皮肤模型构建及外用制剂评价应用，25万，2021/6-2024/6，在研，主持

(6) 中央高校基本科研业务费重点项目，以患者为中心基于治疗行为数据的药物治疗智能管理与服务平台研究，60万，2019/08-2021/07，已结题，主持

(7) 中央高校基本科研业务费项目，中性粒细胞膜仿生纳米粒用于重症新型冠状病毒肺炎伴细胞因子风暴的治疗研究，10万，2020/01-2020/12，已结题，主持

(8) 上海市科委“科技创新行动计划”港澳台科技合作项目，19410761200，基于整体识别的药物纳米晶自稳定化Pickering乳口服后命运与作用机制研究，2019/9-2022/8，40万元，已结题，参加

(9) 上海市“科技创新行动计划”“一带一路”国际合作项目，19430741500，基于药物纳米晶的共递送系统与动脉粥样硬化治疗，2019/11-2021/10，30万元，已结题，参加

(10) 上海市“科技创新行动计划”生物医药领域科技支撑项目， 1940190070，龙葵银消片的新药临床前研究，2019/04— 2022/03 ，70万元，已结题，参加

(11)  上海市“科技创新行动计划”“一带一路”国际合作项目，18410741800，基于整体识别的荧光杂化纳米结晶经口服体内命运与作用机制研究，2018/10-2020/09，30万元，已结题，参加

(12)  国家自然科学基金青年科学基金项目，81703434，基于整体识别的靶向抗原提呈细胞纳米乳经皮免疫及机制研究，2018/01-2020/12，19.5万元，已结题，参加

(13)  国家自然科学基金青年科学基金项目，81602744，中国汉族人特应性皮炎易感基因FLG的精细定位与功能研究，2017/01-2019/12，17万元，已结题，参加

(14) 上海市“科技创新行动计划”医学和农业领域科技支撑项目，15401972100 ，蒲莲清解颗粒申报新药的临床前研究，2015/07 — 2019/09 ，50万元，已结题，主持

(15) 上海市卫计委重点项目，201440025、以缺氧诱导因子-1α为沉默靶点的黑素瘤基因治疗的纳米靶向载体系统构建及实验研究， 2015/01 — 2017/12 ，10万元，已结题，主持

(1) 国家自然科学基金面上项目， 82373274，融合记忆样NK细胞-焦亡肿瘤的仿生囊泡型疫苗新策略及抗黑色素瘤转移的机制研究，49万，2024/01-2027/12，在研，主持

(2) 国家自然科学基金面上项目，82073385，富氧M1型巨噬细胞携载光敏药物用于肿瘤供氧干预和光动力协同治疗的机制研究，55万，2021/01-2024/12，在研，主持

(3)上海市“科技创新行动计划”上海工程技术研究中心与专业技术服务平台项目，20DZ2255200，上海中药外用制剂创新工程技术研究中心，500万，2020/12-2022/11，已结题，主持

(4) 上海市“科技创新行动计划”生物医药科技支撑项目，23S11901300，基于PROTAC技术的高选择性JAK1降解剂外用治疗特应性皮炎的临床前研究，40万，2023/04-2026/03，在研，主持

(5) 上海市“科技创新行动计划” 实验动物研究领域项目, 21140901900，基于 3D 生物打印技术的人体皮肤模型构建及外用制剂评价应用，25万，2021/6-2024/6，在研，主持

(6) 中央高校基本科研业务费重点项目，以患者为中心基于治疗行为数据的药物治疗智能管理与服务平台研究，60万，2019/08-2021/07，已结题，主持

(7) 中央高校基本科研业务费项目，中性粒细胞膜仿生纳米粒用于重症新型冠状病毒肺炎伴细胞因子风暴的治疗研究，10万，2020/01-2020/12，已结题，主持

(8) 上海市科委“科技创新行动计划”港澳台科技合作项目，19410761200，基于整体识别的药物纳米晶自稳定化Pickering乳口服后命运与作用机制研究，2019/9-2022/8，40万元，已结题，参加

(9) 上海市“科技创新行动计划”“一带一路”国际合作项目，19430741500，基于药物纳米晶的共递送系统与动脉粥样硬化治疗，2019/11-2021/10，30万元，已结题，参加

(10) 上海市“科技创新行动计划”生物医药领域科技支撑项目， 1940190070，龙葵银消片的新药临床前研究，2019/04— 2022/03 ，70万元，已结题，参加

(11)  上海市“科技创新行动计划”“一带一路”国际合作项目，18410741800，基于整体识别的荧光杂化纳米结晶经口服体内命运与作用机制研究，2018/10-2020/09，30万元，已结题，参加

(12)  国家自然科学基金青年科学基金项目，81703434，基于整体识别的靶向抗原提呈细胞纳米乳经皮免疫及机制研究，2018/01-2020/12，19.5万元，已结题，参加

(13)  国家自然科学基金青年科学基金项目，81602744，中国汉族人特应性皮炎易感基因FLG的精细定位与功能研究，2017/01-2019/12，17万元，已结题，参加

(14) 上海市“科技创新行动计划”医学和农业领域科技支撑项目，15401972100，蒲莲清解颗粒申报新药的临床前研究，2015/07 — 2019/09 ，50万元，已结题，主持

(15) 上海市卫计委重点项目，201440025、以缺氧诱导因子-1α为沉默靶点的黑素瘤基因治疗的纳米靶向载体系统构建及实验研究， 2015/01— 2017/12 ，10万元，已结题，主持

近5年代表性论著

1.       Ying Li ,Zongguang Tai, Jinyuan Ma, Fengze Miao, Rujuan Xin, Cuie Shen, MinShen,Quangang Zhu* and Zhongjian Chen*.Lycorinetransfersomes modified with cell-penetrating peptides for topical treatment of cutaneoussquamous cell carcinoma.Journal of Nanobiotechnology (2023) 21:139. IF 9.429Q1

2.       Lisha Li;Zongguang Tai; Xiying Wu; Junchao Wu; Tingrui Zhang; Zhongjian Chen*;Quangang Zhu*. Ionic liquids: momentous tools in transdermal delivery ofbiomacromolecules, Advanced therapeutics, 2023, 2200332. IF 5.0 Q2

3.       TingruiZhang; Lu Li; Suticha Chunta; Wei Wu; Zhongjian Chen*; Yi Lu*. Enhancedoral bioavailability from food protein nanoparticles: A mini review, Journalof controlled release, 2023 ,354: 146-154. IF11.5 Q1

4.       Yuze Sheng; Zhongjian Chen; Wei Wu; Yi Lu*. Engineered organic nanoparticles to combat biofilms, Drugdiscovery today, 2023 Feb;28(2):103455. IF 8.4 Q1

5.       HuanhuanGuo, Zongguang Tai, Fang Liu, Jing Tian, Nan Din, Zhongjian Chen*, ShenGao*. Research andapplication of kupffer cell thresholds for bsa nanoparticles. Molecules. 2023Jan 16;28(2):880. IF 5.0 Q2

6.       Xinyue Zhang, Zongguang Tai, Fengze Miao, Hao Huang, Quangang Zhu, LeileiBao*, Zhongjian Chen*. Metabolism heterogeneity in melanoma fuelsdeactivation of immunotherapy: Predict before protect. Front Oncol. 2022 Dec22;12:1046102. IF 5.7 Q2

7.       Xiying Wu; Min Shen ; Huan Wang; Xue He; Jingwen Tan; Ruiping Wang;Lianjuan Yang; Hong Yang; Jianping Qi*; Zhongjian Chen*; Quangang Zhu*. Evaluation of the efficacy and safety ofionic liquids containing ketoconazole in patients with tinea pedis: Arandomized controlled clinical trial. Bioengineering & translationalmedicine, 2022;e10463. IF 10.684 Q1

8.       LeiLi; Congcong Zhu; Quangang Zhu*; Zhongjian Chen*; Xike Gao*.Design,synthesis and bioactivity evaluation of guaiazulene derivatives withantioxidant and anti-inflammatory activities, Chinese journal of organicchemistry, 2022,42(9): 2906-2913.

9.       Juan Wang,Baiping Cui, Zhongjian Chen, Xiaolei Ding*. The regulation of skin homeostasis,repair and the pathogenesis of skin diseases by spatiotemporal activation ofepidermal mTOR signaling. Front Cell Dev Biol. 2022 Jul 22;10:950973. IF 6.1Q2

10.    Rongrong Chai, Zongguang Tai, YunjieZhu, Chaochao Chai, Zhongjian Chen, Quangang Zhu*.Symbioticmicroorganisms: prospects for treating atopic dermatitis. Expert Opin BiolTher. 2022 Jul;22(7):911-927. IF 5.6

11.    Huirong Jiang, Zongguang Tai, HuijunPan, Zhen Cui, Rongrong Chai, Congcong Zhu, Jing Tian, Leilei Bao, QuangangZhu*, Zhongjian Chen*. Macrophage membrane-derived biomimeticnanoparticles for treatment of cytokine release syndrome. J Biomed Nanotechnol.2022 Apr 1;18(4):1064-1074. IF 3.6 Q3

12.    Xiying Wu, Jingjing Xuan, Qin Yu,Wei Wu, Yi Lu, Quangang Zhu, Zhongjian Chen, Jianping Qi*.ConvertingTretinoin into Ionic Liquids for Improving Aqueous Solubility and Permeabilityacross Skin. Pharm Res. 2022 Oct;39(10):2421-2430. IF 4.6

13.   Zhiliang Yu, Hong Wang, Zhongjian Chen, Xiaochun Dong, Weili Zhao*,Yuling Shi*, Quangang Zhu*. Discoveryof an Amino Acid-Modified Near-Infrared Aza-BODIPY Photosensitizer as an ImmuneInitiator for Potent Photodynamic Therapy in Melanoma. J Med Chem. 2022 Feb24;65(4):3616-3631. IF 8.0

14.    Kosheli Thapa Magar;George Frimpong Boafo; Xiaotong Li; Zhongjian Chen*; WeiHe*.Liposome-based delivery of biological drugs. Chinese chemical letters, 2022,33(2):587-596. IF 8.5 Q1

15.    Zhenying Guo, Li Shen, Ningning Li,Xiaoxiao Wu, Canming Wang, Zheng Gu 7, Zhongjian Chen, Junping Liu,Weimin Mao, Yuchen Han*. Aurora Kinase A as a Diagnostic and Prognostic Markerof Malignant Mesothelioma. Front Oncol. 2021 Dec 8;11:789244. IF 5.7

16.    Makhloufi Zoulikha, Qingqing Xiao,George Frimpong Boafo, Marwa A. Sallam , Zhongjian Chen, Wei He*.Pulmonary deliveryof siRNA against acute lung injury/acuterespiratory distress syndrome.Acta Pharm Sin B,2022 ,12(2):600-620.IF 14.9

17.   Tingrui Zhang; Zongguang Tai; Zhen Cui; Chai Rongrong; Quangang Zhu*; Zhongjian Chen*. Nano-engineered immune cells as "guidedmissiles" for cancer therapy. Journal of Controlled Release ,2022, 341:60-79. IF 11.5 Q1

18.    Zirong Dong, Wenjuan Liu, KaihengLiu, Yi Lu, Wei Wu, Jianping Qi*, ZhongjianChen*. Effects on immunization of the physicochemical parameters of particles as vaccine carriers. DrugDiscovery Today, 2021 ,26(7):1712-1720. IF 8.4 Q1

19.   Xiying Wu,Quangang Zhu, Zhongjian Chen, WeiWu, Yi Lu, Jianping Qi*.Ionic liquids as a useful tool for tailoring activepharmaceutical ingredients. Journal of Controlled Release, 2021, 338: 268-283. IF11.5 Q1

20.    Wenjuan Liu, Zirong Dong, KaihengLiu, Yi Lu, Wei Wu, Jianping Qi*, Zhongjian Chen*.Targeting strategies of oralnano-delivery systems for treating inflammatory bowel disease. Int J Pharm, 2021,600:120461. IF 6.5 Q1

21.    Quangang Zhu# , Zhongjian Chen#, Pijush Kumar Paul, Yi Lu, WeiWu*,Jianping Qi*. Oral delivery of proteins and peptides: Challenges, statusquoand future perspectives. Acta Pharmaceutica Sinica B. 2021, 11(8):2416-2448. IF 14.9 Q1

22.    Yanping Huang#, Qin Yu#,Zhongjian Chen, Wei Wu, QuangangZhu*, Yi Lu *. In vitro and in vivo correlationfor lipid-based formulations: current status and future perspectives. Acta Pharm Sin B. 2021, 11(8),2469-2487. IF 14.9

23.   Qingqing Xiao, Xiaotong Li, Yi Li, Zhenfeng Wu, Chenjie Xu, Zhongjian Chen, Wei He*. Biological drug and drug delivery-mediated immunotherapy. ActaPharmaceutica Sinica B, 2021;11(4):941-960. IF 14.9

24.    Xiaochun Wang, Imran Shair Mohammad,Lifang Fan,Zongmin Zhao, Md Nurunnabi, Marwa A. Sallam, Jun Wu, Zhongjian Chen, Lifang Yin*, Wei He*.Deliverystrategies of amphotericin B for invasive fungal infections. Acta Pharmaceutica Sinica B, 2021;11(8):2585-2604. IF 14.9

25.    Fei Xia, Zhongjian Chen, Quangang Zhu, Jianping Qi, Xiaochun Dong, WeiliZhao, Wei Wu, Yi Lu*. Gastrointestinal lipolysis and trans-epithelial transportof SMEDDS via oral route. Acta Pharmaceutica Sinica B 2021,11(4):1010-1020. IF14.9

26.   Zongguang Tai, Jinyuan Ma, Jianing Ding, Huijun Pan, Rongrong Chai, CongcongZhu, Zhen Cui, Zhongjian Chen*, QuangangZhu*. Aptamer-Functionalized DendrimerDelivery of Plasmid-Encoding lncRNA MEG3 Enhances Gene Therapy inCastration-Resistant Prostate Cancer. International Journal ofNanomedicine, 2020:15 10305–10320. IF 7.0 Q1

27.    Zongguang Tai, Yanping Huang,Quangang Zhu, Wei Wu, Tao Yi, Zhongjian Chen*, Yi Lu *. Utility of Pickering emulsions in improved oral drugdelivery. Drug Discovery Today, 2020, 25(11):2038-2045. IF 8.4 Q1

28.    Zhongjian Chen，Jingjing He，Jianping Qi，Quangang Zhu，Yi Lu. Long-acting microneedles: a progress report of thestate-of-the-art techniques. Drug Discovery Today, 2020, 25(8): 1462-1468. IF 8.4 Q1

29.    Zhongjian Chen, Wei Wu, Yi Lu. What is the futurefor nanocrystal-based drug-delivery systems? Therapeutic Delivery, 2020, 11(4):225-229. IF 0.5

30.    Ejaj Ahmad, Yongjiu Lv, Quangang Zhu,Jianping Qi, Xiaochun Dong, Weili Zhao,  ZhongjianChen, Wei Wu, Yi Lu∗. TAT modification facilitatesnose-to-brain transport of intact mPEG-PDLLA micelles: evidence fromaggregation-caused quenching probes. Applied Materials Today, 2020, 19: 100556.IF 8.7

31.    Weizi Huang, Xiying Wu, Jianping Qi,Quangang Zhu, Wei Wu, Yi Lu*, ZhongjianChen*. Ionic liquids: green and tailor-made solvents in drug delivery. DrugDiscovery Today, 2020, 25(5): 901-908. IF 8.4 Q1

32.   Yongli Song#, Christian F Guerrero-Juarez#, ZhongjianChen#, Yichen Tang, Xianghui Ma, Cong Lv, Xueyun Bi, Min Deng, Lina Bu,Yuhua Tian, Ruiqi Liu, Ran Zhao, Jiuzhi Xu, Xiaole Sheng, Sujuan Du, YeqiangLiu, Yunlu Zhu, Shi-Jun Shan, Hong-Duo Chen, Yiqiang Zhao, Guangbiao Zhou,Jianwei Shuai, Fazheng Ren, Lixiang Xue, Zhaoxia Ying, Xing Dai, Christopher JLengner, Bogi Andersen, Maksim V Plikus, Qing Nie, Zhengquan Yu*. The Msi1-mTOR pathway drives thepathogenesis of mammary and extramammary Paget's disease. Cell research. 2020Oct;30(10):854-872. IF 46.4 Q1

33.   XiyingWu, Qin Yu, Jing Wu, Tian Li, Ning Ding, Wei Wu, Yi Lu, Quangang Zhu, ZhongjianChen, Jianping Qi*. Ionic liquids containing ketoconazole improving topicaltreatment of T. Interdigitale infection by synergistic action. Int J Pharm.2020 Sep 3;589:119842. IF 6.5

34.   Rujuan Xin, Zhongjian Chen, Jin Fu, Fuming Shen,Quangang Zhu*, Fang Huang*.  Xanomeline Protects Cortical Cells FromOxygen-Glucose Deprivation via Inhibiting Oxidative Stress and Apoptosis. FrontPhysiol. 2020 Jun 12;11:656. IF 4.8

35.   ChaoTeng, Chenshi Lin, Feifei Huang, Xuyang Xing, Shenyu Chen, Ling Ye, Helena SAzevedo, Chenjie Xu, Zhengfeng Wu, Zhongjian Chen, Wei He*.Intracellular codelivery of anti-inflammatory drug and anti-miR 155 to treatinflammatory disease. Acta Pharm Sin B. 2020 Aug;10(8):1521-1533. IF 14.9

36.   Xiying Wu#; Zhongjian Chen#;Yang Li#;Qin Yu; Yi Lu; Quangang Zhu; Ying Li; Duopeng An; Jianping Qi*; Wei Wu*. Improvingdermal delivery of hydrophilic macromolecules by biocompatible ionic liquidbased on choline and malic acid. International journal of pharmaceutics,2019(558):380-387. IF 6.5 Q1

37.   Yang Li*, Xiying Wu*, Quangang Zhu, Zhongjian Chen, Yi Lu,Jianping Qi#, Wei Wu. Improving the hypoglycemic effect ofinsulin via the nasal administration of deep eutectic solvents. Internationaljournal of pharmaceutics, 2019(569):118584. IF 6.5

38.   Zhongjian Chen#; QuangangZhu#; Jianping Qi; Yi Lu; Wei Wu. Sustained and controlled release of herbalmedicines: The concept of synchronized release. International journal of pharmaceutics,2019(560):116-125. IF 6.5 Q1

39.   Congcong Zhu; Yunjie Zhu; Huijun Pan; Zhongjian Chen*;Quangang Zhu*. Current Progresses of Functional Nanomaterials for ImagingDiagnosis and Treatment of Melanoma. Current Topics in Medicinal Chemistry,2019(19):2494-2506. IF 3.6

40.   Zhiliang Yu; Junliang Zhou; Xiaochun Dong; Weili Zhao*; ZhongjianChen*; Visualizing Nitric oxide in mitochondria and lysosomes of livingcells with N-Nitrosation of BODIPY- based fluorescent probes. Analytica chimicaacta, 2019(1067): 88-97. IF6.9 Q1

41.   Xiuhong Lu, Guangyu Lin, Xiaochun Dong*, Weili Zhao*, ZhongjianChen*. Reply to Comment on “Water-Soluble Fluorescent Probe with DualMitochondria/Lysosome Targetability Superoxide Detection in Live Cells and inZebrafish Embryos”.ACS Sensors,2019,4,3084-3087. IF 9.6 Q1

42.   Xianfeng Lin, Xiuhong Lu, Junliang Zhou, Hang Ren,Xiaochun Dong,Weili Zhao∗,Zhongjian Chen∗. Instantaneous fluorescent probe for thespecific detection of H2S. Spectrochim Acta A Mol BiomolSpectrosc,2019,213(15):416-422. IF 4.8 Q1

43.    Ye Li, Chunliu Wang, Shiyu Zong,Jianping Qi, Xiaochun Dong, Weili Zhao, Wei Wu, Qiang Fu∗, Yi Lu∗, and Zhongjian Chen∗. The Trigeminal Pathway Dominatesthe Nose-to-Brain Transportation of Intact Polymeric Nanoparticles:Evidencefrom Aggregation-Caused Quenching Probes. J Biomed Nanotech, 2019, 15(4):686-702. IF 3.6

44.    Dailei Liu, Bo Wan, Jianping Qi,Xiaochun Dong, Weili Zhao, Wei Wu, Yikang Dai*, Yi Lu*, Zhongjian Chen*.Permeation into but not across the cornea: Bioimaging of intact nanoemulsionsand nanosuspensions using aggregation-causedquenching probes. Chinese Chem Lett. 2018, 29(12): 1834-1838. IF 8.4 Q1

45.    Zhongjian Chen, Yongjiu Lu, Jianping Qi, Quangang Zhu, Yi Lu*, WeiWu. Overcoming or circumventing the stratum corneum barrier for efficienttranscutaneous immunization. Drug Discov Today, 2018, 23(1):181-186. IF 8.4

46.   JianZhang, Xin Ji, Hang Ren, Junliang Zhou, Zhongjian Chen*, Xiaochun Dong*, Weili Zhao*. Meso-heteroaryl BODIPY dyesas dual-responsive fluorescent probes for discrimination of Cys from Hcy andGSH. Sensors and Actuators B: Chemical,260(2018):861-869. IF 9.2

47.   Jian Zhang, Xin Ji, Junliang Zhou, Zhongjian Chen*, Xiaochun Dong*, Weili Zhao*. Pyridinium substituted BODIPYas NIR fluorescent probe for simultaneous sensing of hydrogen sulphide/glutathioneand cysteine/homocysteine. Sensors and Actuators B: Chemical,257(2018):1076-1082. IF 9.2

48.   Junliang Zhou, Shuang Xu, Xiaochun Dong*, Zhongjian Chen*, Weili Zhao*. Near-infrared off-onfluorescent probe for fast and selective detection of palladium (II) in livingcells. Journal of photochemistry and photobiology a:chemistry,355(2018):158-164. IF 5.1

49.   Xiuhong Lu, Zhongjian Chen*, Xiaochun Dong*, Weili Zhao*. Water-SolubleFluorescent Probe with Dual Mitochondria/Lysosome Targetability for SelectiveSuperoxide Detection in Live Cells and in Zebrafish Embryos. ACSSensors,2018,3,59-64. IF 9.6

50.    Qin Yu, Xiying Wu, Quangang Zhu, WeiWu, Zhongjian Chen*, Ye Li*, Yi Lu*. Enhanced transdermal delivery ofmeloxicam by nanocrystals: preparation, in vitro and in vivo evaluation. AsianJ Pharm Sci, 2018, 13(6): 518-526. IF 9.3

代表性专利

(1)陈中建; 朱全刚; 谢欣辛; 潘会君; 谢韶琼; 姜文成; 张红敏; 连天雁; 李莹; 朱聪聪; 一种治疗化脓性皮肤病的中药颗粒、制备方法及其应用,2021-8-17, 中国,ZL 201910616615.X

(2) 沈敏;朱全刚; 陈中建;谢欣辛;张红敏;喻琴; 连天雁; 朱聪聪; 潘会君;信如娟;一种治疗银屑病的中药组合物及其制备方法和应用，2021-6-22,中国,

ZL 201910837376.0

(3) 陈中建; 朱全刚; 朱聪聪; 潘会君; 薛继竞; 江海平; 李纪平; 张红敏；一种用于皮肤保湿和屏障修复的护肤品及其制备方法，2021-3-30，中国，

ZL 201811033414.9

(4) 朱全刚; 陈中建; 孟鸽飞; 朱聪聪; 李莹; 沈敏; 信如娟; 潘会君; 一种治疗癌痛、腹水的中药组合物,中药贴膏及其制备方法, 2021-3-12, 中国,

ZL 201810501430.X

(5) 朱全刚; 陈中建; 朱聪聪;潘会君;谢韶琼; 姜文成; 柴蓉蓉; 姜泽静; 谢欣辛;一种治疗湿疹的中药组合物及制备方法和应用,2020-11-24, 中国,

ZL 201710647984.6

(6) 陈中建; 朱全刚; 丁佳宁; 信如娟; 沈敏; 安多朋; 潘会君; 武喜营; 喻琴;李莹; EpDT3适配体修饰的前列腺癌靶向给药载体、递送系统及其制备与应用,2020-9-15, 中国,ZL201810572286.9

(7) 朱全刚; 陈中建; 李莹; 信如娟; 刘业强; 沈翠娥; 张红敏; 安多朋; 潘会君; 一种靶向抗恶性黑色素瘤的达卡巴嗪和miR-205共载外泌体及其制备方法和应用, 2020-7-28, 中国, ZL 201710652656.5

(8) 陈中建; 朱全刚; 安多朋; 沈敏; 石磊; 丁佳宁; 孟鸽飞; 武喜营; 喻琴; 一种靶向抗皮肤鳞状细胞癌的共载超级变形脂质体及其制备方法和应用,2020-6-23, 中国,  ZL 201710647498.4

(9) 朱全刚; 陈中建; 童仙君; 徐蓓蕾; 张若曦; 一种前列腺癌超声诊断靶向试剂及制备方法, 2017-01-11, 中国, ZL 2014 1 0200726.X

(10) 朱全刚; 张树辉; 张欢欢; 陈中建; 朱聪聪; 潘会君; 柴蓉蓉; 海藻玉壶汤及其活性成分岩藻黄质在制备治疗肝癌的药物中的应用,2019-4-24, 中国, 申请号201910335460.2